Galena Biopharma Receives Notice of Allowance of U.S. Patent Application for GALE-401 (Anagrelide Controlled Release) Composition of Matter

Galena Biopharma (GALE) Receives NoA from USPTO for GALE-401 Patent App

Galena Biopharma (NASDAQ: GALE) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application for GALE-401 composition of matter. GALE-401 is a controlled release formulation of anagrelide for use in reducing platelet counts in patients with... More